BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8837357)

  • 1. Disappearance of antibodies to Cromer blood group system antigens during mid pregnancy.
    Reid ME; Chandrasekaran V; Sausais L; Pierre J; Bullock R
    Vox Sang; 1996; 71(1):48-50. PubMed ID: 8837357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemagglutination inhibition of Cromer blood group antibodies with soluble recombinant decay-accelerating factor.
    Daniels GL; Green CA; Powell RM; Ward T
    Transfusion; 1998 Apr; 38(4):332-6. PubMed ID: 9595014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequestration of anti-Cra in the placenta: serologic demonstration by placental elution.
    Weber SL; Bryant BJ; Indrikovs AJ
    Transfusion; 2005 Aug; 45(8):1327-30. PubMed ID: 16078921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent anti-Dra in two pregnancies.
    Rahimi-Levene N; Kornberg A; Siegel G; Morozov V; Shinar E; Asher O; Levene C; Yahalom V
    Immunohematology; 2005; 21(3):126-8. PubMed ID: 16178671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Cromer blood group system: a review.
    Storry JR; Reid ME; Yazer MH
    Immunohematology; 2010; 26(3):109-18. PubMed ID: 21214297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GUTI: a new antigen in the Cromer blood group system.
    Storry JR; Sausais L; Hue-Roye K; Mudiwa F; Ferrer Z; Blajchman MA; Lublin DM; Ma BW; Miquel JF; Nervi F; Pereira J; Reid ME
    Transfusion; 2003 Mar; 43(3):340-4. PubMed ID: 12675719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAF.
    Telen MJ; Hall SE; Green AM; Moulds JJ; Rosse WF
    J Exp Med; 1988 Jun; 167(6):1993-8. PubMed ID: 2455016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mapping of the Cromer blood group Cra and Tca epitopes of decay accelerating factor: toward the use of recombinant antigens in immunohematology.
    Telen MJ; Rao N; Udani M; Thompson ES; Kaufman RM; Lublin DM
    Blood; 1994 Nov; 84(9):3205-11. PubMed ID: 7524769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decay-accelerating factor (CD55) deficiency phenotypes in Japanese.
    Daniels GL; Green CA; Mallinson G; Okubo Y; Hori Y; Kataoka A; Kaihara M
    Transfus Med; 1998 Jun; 8(2):141-7. PubMed ID: 9675792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Cromer blood group system: a review.
    Storry JR; Reid ME
    Immunohematology; 2002; 18(4):95-103. PubMed ID: 15373545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular basis of Cromer blood group antigens.
    Lublin DM; Kompelli S; Storry JR; Reid ME
    Transfusion; 2000 Feb; 40(2):208-13. PubMed ID: 10686005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cromer-related antigens--blood group determinants on decay-accelerating factor.
    Daniels G
    Vox Sang; 1989; 56(4):205-11. PubMed ID: 2474898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D analysis of CROMER (DAF) and a new antigen CRAG.
    Floch A; Vege S; Hue-Roye K; Hamilton JR; Williams LA; Choate J; Lomas-Francis C; Westhoff CM
    Blood Transfus; 2022 Nov; 20(6):483-488. PubMed ID: 35175190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serological investigation and clinical significance of high-titer, low-avidity (HTLA) antibodies.
    Moulds MK
    Am J Med Technol; 1981 Oct; 47(10):789-95. PubMed ID: 7199253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemolytic disease of the newborn because of rare anti-Vel.
    van Gammeren AJ; Overbeeke MA; Idema RN; van Beek RH; Ten Kate-Booij MJ; Ermens AA
    Transfus Med; 2008 Jun; 18(3):197-8. PubMed ID: 18598283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of an anti-Dia antibody causing hemolytic disease in a newborn infant.
    Alves de Lima LM; Berthier ME; Sad WE; DiNapoli J; Johnson CL; Marsh WL
    Transfusion; 1982; 22(3):246-7. PubMed ID: 7090038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular basis of reduced or absent expression of decay-accelerating factor in Cromer blood group phenotypes.
    Lublin DM; Mallinson G; Poole J; Reid ME; Thompson ES; Ferdman BR; Telen MJ; Anstee DJ; Tanner MJ
    Blood; 1994 Aug; 84(4):1276-82. PubMed ID: 7519480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Cromer blood group system: an update.
    Storry JR; Lomas-Francis C
    Immunohematology; 2021 Sep; 37(3):118-121. PubMed ID: 34591381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three new high-prevalence antigens in the Cromer blood group system.
    Hue-Roye K; Lomas-Francis C; Belaygorod L; Lublin DM; Barnes J; Chung A; Fung-Kee-Fung K; Kinney J; Goldman-Lavi R; Yahalom V; Poole J; Ivankovic Z; Alcantara D; Bekavac M; Cepulic BG; Velliquette RW; Mason R; Reid ME
    Transfusion; 2007 Sep; 47(9):1621-9. PubMed ID: 17725726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemolytic transfusion reaction due to anti-Tc(a).
    Kowalski MA; Pierce SR; Edwards RL; Ethirajan S; Ryan K; Livergood MP
    Transfusion; 1999 Sep; 39(9):948-50. PubMed ID: 10533820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.